Oculopharyngeal muscular dystrophy

Oculopharyngeal muscular dystrophy (OPMD) is a rare genetic muscle disorder characterized by slowly progressive weakness of specific muscle groups, primarily those controlling the eyelids and swallowing. The disease typically begins in adulthood, usually after age 40–50, and is caused by an abnormal expansion of a GCN trinucleotide repeat in the PABPN1 gene (poly(A) binding protein nuclear 1) on chromosome 14q11.2. This expansion leads to the production of an abnormal protein that accumulates as intranuclear filamentous inclusions in muscle cells, ultimately causing muscle degeneration. The hallmark symptoms of OPMD are progressive ptosis (drooping of the eyelids) and dysphagia (difficulty swallowing), which result from weakness of the levator palpebrae superioris muscles and the pharyngeal muscles, respectively. As the disease progresses, proximal limb weakness may develop, particularly affecting the hip and shoulder girdle muscles, leading to difficulty climbing stairs, walking, and raising the arms. Some patients also experience dysphonia (voice changes) and, in advanced stages, tongue weakness. Dysphagia can lead to serious complications including aspiration pneumonia, malnutrition, and weight loss. There is currently no cure for OPMD, and treatment is primarily supportive and symptomatic. Surgical interventions such as blepharoplasty or frontalis suspension can address ptosis and help maintain the visual field. Cricopharyngeal myotomy or dilation may improve swallowing function in patients with significant dysphagia. Dietary modifications, speech therapy, and nutritional support are important components of management. Physical therapy can help maintain mobility and muscle strength. Research into potential therapies, including gene therapy and anti-aggregation strategies targeting the intranuclear inclusions, is ongoing.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Oculopharyngeal muscular dystrophy